These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32153573)

  • 1. New Approaches to Targeting B Cells for Myasthenia Gravis Therapy.
    Huda R
    Front Immunol; 2020; 11():240. PubMed ID: 32153573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.
    Beecher G; Putko BN; Wagner AN; Siddiqi ZA
    Drugs; 2019 Mar; 79(4):353-364. PubMed ID: 30762205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies.
    Dalakas MC
    Curr Opin Neurol; 2020 Oct; 33(5):545-552. PubMed ID: 32833750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.
    Stathopoulos P; Kumar A; Nowak RJ; O'Connor KC
    JCI Insight; 2017 Sep; 2(17):. PubMed ID: 28878127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myasthenia gravis: from autoantibodies to therapy.
    Mantegazza R; Bernasconi P; Cavalcante P
    Curr Opin Neurol; 2018 Oct; 31(5):517-525. PubMed ID: 30156572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.
    Lazaridis K; Tzartos SJ
    Front Immunol; 2020; 11():212. PubMed ID: 32117321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen specific B cells in myasthenia gravis patients.
    Takata K; Kinoshita M; Mochizuki H; Okuno T
    Immunol Med; 2020 Jun; 43(2):65-71. PubMed ID: 32046601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cells in the pathophysiology of myasthenia gravis.
    Yi JS; Guptill JT; Stathopoulos P; Nowak RJ; O'Connor KC
    Muscle Nerve; 2018 Feb; 57(2):172-184. PubMed ID: 28940642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on immune-mediated therapies for myasthenia gravis.
    Habib AA; Ahmadi Jazi G; Mozaffar T
    Muscle Nerve; 2020 Nov; 62(5):579-592. PubMed ID: 32462710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
    Vincent A; Leite MI
    Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ; Oshima M; Deitiker P
    Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune mechanisms in myasthenia gravis.
    Cavalcante P; Bernasconi P; Mantegazza R
    Curr Opin Neurol; 2012 Oct; 25(5):621-9. PubMed ID: 22941261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 17-Mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis.
    Yoshikawa H; Lambert EH; Walser-Kuntz DR; Yasukawa Y; McCormick DJ; Lennon VA
    J Immunol; 1997 Aug; 159(3):1570-7. PubMed ID: 9233656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation and autoimmune myasthenia gravis.
    Huda R
    Front Immunol; 2023; 14():1110499. PubMed ID: 36793733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myasthenia gravis and the neuromuscular junction.
    Querol L; Illa I
    Curr Opin Neurol; 2013 Oct; 26(5):459-65. PubMed ID: 23945282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myasthenia gravis and specific immunotherapy: monoclonal antibodies.
    Cai XJ; Li ZW; Xi JY; Song HZ; Liu J; Zhu WH; Guo Y; Jiao Z
    Ann N Y Acad Sci; 2019 Sep; 1452(1):18-33. PubMed ID: 31393614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis.
    Berrih-Aknin S; Ragheb S; Le Panse R; Lisak RP
    Autoimmun Rev; 2013 Jul; 12(9):885-93. PubMed ID: 23537509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myasthenia gravis: Molecular mechanisms and promising therapeutic strategies.
    Chen X; Qiu J; Gao Z; Liu B; Zhang C; Yu W; Yang J; Shen Y; Qi L; Yao X; Sun H; Yang X
    Biochem Pharmacol; 2023 Dec; 218():115872. PubMed ID: 37865142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of immunopathological features of AChR/MuSK autoantibody-negative myasthenia gravis.
    Hayashi A; Shiono H; Ohta M; Ohta K; Okumura M; Sawa Y
    J Neuroimmunol; 2007 Sep; 189(1-2):163-8. PubMed ID: 17706794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation.
    Le Panse R; Berrih-Aknin S
    Curr Opin Neurol; 2013 Oct; 26(5):569-76. PubMed ID: 23995274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.